All Stories

  1. Ceramides accumulation and complement activation in patients with EMRN
  2. Piroheptine for Treating Parkinson
  3. Mazaticol for Treating Parkinson
  4. Acknowledgments
  5. Detection of human herpesviruses in cerebrospinal fluids collected from patients suspected of neuroinfectious diseases
  6. Detection of circulating tumor DNA in cerebrospinal fluid prior to diagnosis of spinal cord lymphoma by flow cytometric and cytologic analyses
  7. Corrigendum to “Galabiosylceramide is present in human cerebrospinal fluid”
  8. Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment
  9. Review article for the close relationship between neuroinflammation and glycosphingolipids
  10. Galabiosylceramide is present in human cerebrospinal fluid
  11. Clioquinol kills astrocyte-derived KT-5 cells by the impairment of the autophagy–lysosome pathway
  12. Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome
  13. cross-talk between Trk neurotrphin receptor and innate immunity
  14. Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease
  15. Mazaticol for Treating Parkinson
  16. Better neuroradiological approach for the diagnosis of early-stage Parkinson's disease patients
  17. Piroheptine for Treating Parkinson
  18. Altered regulation of serum lysosomal acid hydrolase activities in Parkinson's disease: A potential peripheral biomarker?
  19. A Patient With Thiamine Deficiency Exhibiting Muscle Edema Suggested by MRI
  20. Changes in Serial D-Dimer Levels Predict the Prognoses of Trousseau's Syndrome Patients
  21. Anti-GM1 ganglioside antibodies modulate membrane-associated sphingomyelin metabolism by altering neutral sphingomyelinase activity
  22. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study
  23. Usefulness of combining 123 I-FP-CIT-SPECT striatal asymmetry index and cardiac 123 I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms
  24. MR neurography for the evaluation of CIDP
  25. Differentiation of cancer from atrial fibrillation in patients with acute multifocal stroke
  26. encephalomyeloradiculoneuropathy patient showing anti-neutral glycolipids antibodies and epilepsy
  27. brain abscess
  28. Retrospective analysis of parkinsonian patients exhibiting normal 123I-MIBG cardiac uptake
  29. Voriconazole-responsive Disseminated Nodular Lesions on Spinal MRI
  30. Neurotropin promotes NGF signaling through interaction of GM1 ganglioside with Trk neurotrophin receptor in PC12 cells
  31. Hypertrophic pachymeningitis and encephalitis in a patient with relapsing polychondritis
  32. An update on diagnostic imaging studies for viral encephalitis
  33. Winged scapula in patients with myotonic dystrophy type 1
  34. Extracorporeal Aβ removal system (EARS) for Alzheimer's disease therapy: Novel devices with fragments of hollow fibers removed Aβ effectively both in vitro and in vivo
  35. Glycobiology and neurological disorders
  36. Transient Splenial Lesion of the Corpus Callosum in H1N1 Influenza Virus-Associated Encephalitis/Encephalopathy
  37. Neurotrophin Levels in Cerebrospinal Fluid of Adult Patients with Meningitis and Encephalitis
  38. Stimulated neuronal expression of brain-derived neurotrophic factor by Neurotropin
  39. Novel therapeutic approach for Alzheimer’s disease by removing amyloid β protein from the brain with an extracorporeal removal system
  40. Muscle MRI in Myotonic Dystrophy Type 1 with Foot Drop
  41. Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells
  42. Toward the novel method of treatment for Alzheimer's disease: Extra-corporeal Aβ removal system (EARS)
  43. Electroretinograms in three cases of Creutzfeldt-Jakob disease with visual disturbances
  44. Acute Autonomic, Sensory and Motor Neuropathy: Successful Treatment with IVIg
  45. β-amyloid (25–35) enhances lipid metabolism and protein ubiquitination in cultured neurons
  46. Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
  47. Postinfectious Myeloradiculoneuropathy With Cranial Nerve Involvements Associated With Human Herpesvirus 7 Infection
  48. Impairment of Trk-Neurotrophin Receptor by the Serum of a Patient With Subacute Sensory Neuropathy
  49. Abnormal intracellular trafficking of high affinity nerve growth factor receptor, Trk, in stable transfectants expressing presenilin 1 protein
  50. Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts
  51. Biological Implication of the Membrane Rafts in Neuronal Cells
  52. Spinal Cavitous Hemorrhagic Infarction with Abdominal Aortic Aneurysm
  53. HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, Trk, and morphological differentiation with fatal outcome in PC12 cells
  54. Posterior Thoracic Spinal Cord Infarction: Complication of Thoracoabdominal Aortic Aneurysm
  55. MRI findings of benign monomelic amyotrophy of lower limb
  56. Role of tyrosine phosphorylation of phospholipase C γ1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts
  57. Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts
  58. Expression of GDNF receptor (RET and GDNFR-α) mRNAs in the spinal cord of patients with amyotrophic lateral sclerosis
  59. Influence of endogenous GM1 ganglioside on TrkB activity, in cultured neurons
  60. HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway
  61. Differential signaling cascade of MAP kinase and S6 kinase depends on 3′,5′-monophosphate concentration in Schwann cells: correlation to cellular differentiation and proliferation
  62. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule:
  63. GM1 gangliosidosis type 3 with severe jaw-closing impairment
  64. Chorea-acanthocytosis with polyclonal antibodies to ganglioside GM1
  65. Discovery of ganglioside GM1 for normal function of Trk neurotrophin receptor in neuronal cells.
  66. 1-Methyl-4-phenylpyridinum kills differentiated PC12 cells with a concomitant change in protein phosphorylation
  67. Abundant but Inactive-state gpl40prototrkIs Expressed in Neuroblastomas of Patients with Good Prognosis
  68. The Effect of the B Subunit of Cholera Toxin on the Action of Nerve Growth Factor on PC12 Cells
  69. A microassay for acid β-galactosidase activity toward asialofetuin
  70. Application of a GM1 ganglioside β-galactosidase microassay method to diagnosis of GM1 gangliosidosis
  71. A fluorometric microassay procedure for monitoring the enzymatic activity of GM1-ganglioside β-galactosidase by use of high-performance liquid chromatography